Understanding what happens to therapeutic antibodies and antibody-drug conjugates (ADCs) after they enter a cell is critical to designing targeted […]
Global Business Reports interviews Krishna Kanumuri, MD & CEO Sai Life Sciences on the company’s journey of transformation
3 Dec 2019
A recent edition of Global Business Reports (GBR) on India Pharmaceuticals 2019 features the interview with Krishna Kanumuri, MD & CEO of Sai Life Sciences. In the interview, Krishna provides a glimpse of the 20 years of the company, and how it is building itself for the future.
Here’s an excerpt from the interview:
“Sai Life Sciences is undergoing major transformation. Over a period from 2016 to 2020, our company is quadrupling in capacity. This capacity, combined with our proven track record and commitment to building long term partnerships, will no doubt make Sai Life Sciences the partner of choice for large pharma and small biotechs in bringing new medicines to life.”, says CEO Krishna Kanumuri.
Here is the link to read the full interview.
Related News
Sai Life Sciences plans to set up a new oral solid formulation facility to support small-molecule programs entering early clinical […]
27 Aug 2026
We have successfully scaled up a late-stage GMP intermediate for a large pharmaceutical customer using flow chemistry, marking another step […]